21/10/2026 KEYTRUDA + Padcev receives EC approval for perioperative treatment of resectable MIBC US FDA grants Fast Track designation to Samsung Bioepis' SBE303 ADC for post-enfortumab vedotin advanced urothelial cancer KEYTRUDA + Padcev receives EC approval for perioperative treatment of resectable MIBC (Ref) Merck & Co./MSD announced that the European Commission approved KEYTRUDA® (pembrolizumab; anti-PD-1) + Padcev® (enfortumab vedotin-ejfv; nectin-4 targeted ADC) as perio